FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311400685> ?p ?o ?g. }

• W4311400685 endingPage "101142" @default.
• W4311400685 startingPage "101142" @default.
• W4311400685 abstract "Purpose/Objectives; To report the quality of life (QOL) analysis and toxicity in intermediate-risk prostate cancer patients treated with or without androgen deprivation therapy (ADT) on PCG GU 003.Materials/Methods; Between 2012 and 2019, intermediate-risk prostate cancer patients were enrolled. Patients were randomized to receive moderately hypofractionated proton beam therapy (PBT) to 70 Gy relative biologic effectiveness (RBE) in 28 fractions to the prostate with or without six months of ADT. Expanded Prostate Cancer Index Composite (EPIC), Short-Form 12, and the American Urological Association Symptom Index (AUASI) instruments were given at baseline, 3, 6, 12, 18, and 24 months after PBT. Toxicities were assessed according to Common Terminology Criteria for Adverse Events (Version 4).Results; One hundred ten patients were randomized to PBT either with six months of ADT (n=55) or without ADT (n=55). The median follow-up was 32.4 months (range 5.5-84.6). On average, 101 out of 110 (92%) patients filled out baseline QoL and PRO surveys. The compliance was 84%, 82%, 64%, 42% at 3 months, 6 months, 12 months, and 24 months respectively. Baseline median AUASI was comparable between arms (6 (11%) ADT vs. 5 (9%) no ADT, p=0.359). Acute and late grade 2+ genitourinary (GU) and gastrointestinal toxicity (GI) was similar between arms. The ADT arm experienced a QOL decline of mean scores in the sexual (-16.1, p<0.001) and hormonal (-6.3, p<0.001) domains, with the largest time-specific hormonal differences at 3 (-13.8, p<0.001) and 6 (-11.2, p<0.001) months. The hormonal quality of life domain returned to baseline six months after therapy. There was a trend to baseline in sexual function six months following completion of ADT.Conclusions; Following six months of ADT, sexual and hormonal domains returned to baseline six months following completion of treatment for men with intermediate-risk prostate cancer." @default.
• W4311400685 created "2022-12-26" @default.
• W4311400685 creator A5006151030 @default.
• W4311400685 creator A5016499084 @default.
• W4311400685 creator A5016852500 @default.
• W4311400685 creator A5022932491 @default.
• W4311400685 creator A5023973397 @default.
• W4311400685 creator A5032989774 @default.
• W4311400685 creator A5039358235 @default.
• W4311400685 creator A5046597561 @default.
• W4311400685 creator A5087495484 @default.
• W4311400685 creator A5088829777 @default.
• W4311400685 creator A5091753953 @default.
• W4311400685 date "2023-05-01" @default.
• W4311400685 modified "2023-09-28" @default.
• W4311400685 title "Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003" @default.
• W4311400685 cites W117621210 @default.
• W4311400685 cites W1494104030 @default.
• W4311400685 cites W1513287091 @default.
• W4311400685 cites W1567228155 @default.
• W4311400685 cites W1986114421 @default.
• W4311400685 cites W2003895274 @default.
• W4311400685 cites W2018108128 @default.
• W4311400685 cites W2066899660 @default.
• W4311400685 cites W2074421032 @default.
• W4311400685 cites W2089983916 @default.
• W4311400685 cites W2093867637 @default.
• W4311400685 cites W2096421124 @default.
• W4311400685 cites W2106285196 @default.
• W4311400685 cites W2108864389 @default.
• W4311400685 cites W2110881680 @default.
• W4311400685 cites W2117792530 @default.
• W4311400685 cites W2126639336 @default.
• W4311400685 cites W2131308754 @default.
• W4311400685 cites W2134766389 @default.
• W4311400685 cites W2138634479 @default.
• W4311400685 cites W2142359566 @default.
• W4311400685 cites W2147437760 @default.
• W4311400685 cites W2148497849 @default.
• W4311400685 cites W2160406420 @default.
• W4311400685 cites W2283825277 @default.
• W4311400685 cites W2340422569 @default.
• W4311400685 cites W2466376734 @default.
• W4311400685 cites W3009482232 @default.
• W4311400685 cites W3017283363 @default.
• W4311400685 cites W3084132078 @default.
• W4311400685 cites W3185550549 @default.
• W4311400685 cites W3197969848 @default.
• W4311400685 cites W3208917612 @default.
• W4311400685 cites W4205879532 @default.
• W4311400685 cites W4235780754 @default.
• W4311400685 doi "https://doi.org/10.1016/j.adro.2022.101142" @default.
• W4311400685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36896215" @default.
• W4311400685 hasPublicationYear "2023" @default.
• W4311400685 type Work @default.
• W4311400685 citedByCount "1" @default.
• W4311400685 countsByYear W43114006852023 @default.
• W4311400685 crossrefType "journal-article" @default.
• W4311400685 hasAuthorship W4311400685A5006151030 @default.
• W4311400685 hasAuthorship W4311400685A5016499084 @default.
• W4311400685 hasAuthorship W4311400685A5016852500 @default.
• W4311400685 hasAuthorship W4311400685A5022932491 @default.
• W4311400685 hasAuthorship W4311400685A5023973397 @default.
• W4311400685 hasAuthorship W4311400685A5032989774 @default.
• W4311400685 hasAuthorship W4311400685A5039358235 @default.
• W4311400685 hasAuthorship W4311400685A5046597561 @default.
• W4311400685 hasAuthorship W4311400685A5087495484 @default.
• W4311400685 hasAuthorship W4311400685A5088829777 @default.
• W4311400685 hasAuthorship W4311400685A5091753953 @default.
• W4311400685 hasBestOaLocation W43114006851 @default.
• W4311400685 hasConcept C121608353 @default.
• W4311400685 hasConcept C126322002 @default.
• W4311400685 hasConcept C126894567 @default.
• W4311400685 hasConcept C133507102 @default.
• W4311400685 hasConcept C141071460 @default.
• W4311400685 hasConcept C159110408 @default.
• W4311400685 hasConcept C168563851 @default.
• W4311400685 hasConcept C197934379 @default.
• W4311400685 hasConcept C2777793932 @default.
• W4311400685 hasConcept C2777899217 @default.
• W4311400685 hasConcept C2778311097 @default.
• W4311400685 hasConcept C2779951463 @default.
• W4311400685 hasConcept C2780192828 @default.
• W4311400685 hasConcept C29730261 @default.
• W4311400685 hasConcept C509974204 @default.
• W4311400685 hasConcept C71924100 @default.
• W4311400685 hasConceptScore W4311400685C121608353 @default.
• W4311400685 hasConceptScore W4311400685C126322002 @default.
• W4311400685 hasConceptScore W4311400685C126894567 @default.
• W4311400685 hasConceptScore W4311400685C133507102 @default.
• W4311400685 hasConceptScore W4311400685C141071460 @default.
• W4311400685 hasConceptScore W4311400685C159110408 @default.
• W4311400685 hasConceptScore W4311400685C168563851 @default.
• W4311400685 hasConceptScore W4311400685C197934379 @default.
• W4311400685 hasConceptScore W4311400685C2777793932 @default.
• W4311400685 hasConceptScore W4311400685C2777899217 @default.
• W4311400685 hasConceptScore W4311400685C2778311097 @default.
• W4311400685 hasConceptScore W4311400685C2779951463 @default.

• next